Business ❯ Corporate Strategy ❯ Mergers and Acquisitions ❯ Investment
The deal adds a novel N‑myristoyltransferase inhibitor payload platform and two preclinical ADC candidates to Novartis and shifts the next test to clinical validation and regulatory close.
